PICS THERAPY

Manipulation of senescence pathways for cancer therapy: from experimental models to clinic

Coordinatore	Ente Ospedaliero Cantonale    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	1˙500˙000 €
EC contributo	1˙500˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2010-StG_20091118
Funding Scheme	ERC-SG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-04-01   -   2016-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Ente Ospedaliero Cantonale  Organization address address: Vialle Officina 3 city: Bellinzona postcode: CH-6500 contact info Titolo: Dr. Nome: Andrea Cognome: Alimonti Email: send email Telefono: 390289000000 Fax: +4191 8200 305	CH (Bellinzona)	hostInstitution	1˙500˙000.00
2	Ente Ospedaliero Cantonale  Organization address address: Vialle Officina 3 city: Bellinzona postcode: CH-6500 contact info Titolo: Prof. Nome: Franco Cognome: Cavalli Email: send email Telefono: 41918118666	CH (Bellinzona)	hostInstitution	1˙500˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'This proposal aims to harness a novel type of senescence that we have identified in response to acute Pten inactivation, and which we believe offers a radical therapeutic approach to target the quiescent cancer stem cell in vivo. In characterizing Pten loss Induced Cellular Senescence, which we have named PICS for short, we have discovered that PICS is distinct from other forms of cellular senescence including oncogene-induced senescence (OIS) and replicative senescence. These distinct differences are characterized by a lack of DNA damage and hyper-replication, breaking the current dogma for senescence induction. The ability to induce senescence, an irreversible growth arrest, in cells by targeting Pten signaling, without a requirement for hyper-replication and DNA damage opens up the possibility to target quiescent cells, including stem cells, that have a low proliferative index. This approach has tremendous therapeutic potential and represents one of the most exciting developments for the advancement of prostate cancer therapy in recent years. Through the manipulation of senescence induction pathways we will identify PICS enhancing drugs and redefine the paradigm for cancer therapy. By developing novel mouse models that target prostate stem cells we will evaluate these PICS pro-senescence drugs in a pre-clinical setting. Finally, these results will be cross referenced with data from human prostate stem cells and we will lay the ground work to translate this to the clinical setting, further developing the clinical potential of these findings to eradicate prostate cancer.'